Snipr Biome
Snipr Biome
SNIPR Biome is a clinical-stage company developing CRISPR-based therapeutics to precisely target and eliminate specific bacteria in the human microbiome.
About
What does Snipr Biome do?
SNIPR Biome is a biotechnology company focused on developing a new class of precision antimicrobial drugs based on CRISPR technology. Their platform allows for the targeted removal of specific bacterial strains, addressing issues like antibiotic resistance, gut microbiome dysbiosis, and infectious diseases, while preserving beneficial bacteria.
What is Snipr Biome's revenue?
StartupHub estimates Snipr Biome's annual revenue at $32.4M (range $6.7M to $106.5M, 29% confidence), based on comparable companies in the sector.
What is Snipr Biome's valuation?
StartupHub estimates Snipr Biome's effective valuation at $376.4M (range $242.5M to $582.1M, 14% confidence), based on comparable companies in the sector.
How much funding has Snipr Biome raised?
Snipr Biome has raised a total of $97M in funding. The most recent round on record is Series B.
Where is Snipr Biome headquartered?
Snipr Biome is headquartered in Copenhagen, Denmark.
What industry does Snipr Biome operate in?
Snipr Biome operates in Biotech, MedTech, Genomics, Drug Discovery, Microbiome Engineering, CRISPR Technology.
“Danish biotech SNIPR Biome receives up to €20 million European backing to advance therapies against microbial resistance.”
View on Reddit“SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy (June 1, 2023).”
View on Reddit“SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.